GLP-1s are all the rage. So it should come as no surprise that shares of Mounjaro and Zepbound maker Eli Liily have soared ...

Expectations for both companies are really high. Morningstar estimates the GLP-1 drug market will be worth $200bn by 2031, and analysts expect Eli Lilly and Novo Nordisk to take the lion’s share of it ...

Questor is The Telegraph’s stockpicking column, helping you decode the markets and offering insights on where to invest for ...

A little over a year ago, I took the stage at Livewire Live and made a 'shocking prediction' for 2024: we would witness “the ...

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...

StudyFinds' Dr. Faith Coleman looks at the common mistakes patients make using GLP-1 agonists like Ozempic and Wegovy.

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.

Novo Nordisk AS (NVO) reports a 25% sales increase, upgrades its full-year outlook, and addresses challenges in the insulin ...

Micro-cap stocks are typically categorized as companies with market capitalizations between $50 million and $300 million. However, it's not a hard-and-fast rule. Many small stocks can fluctuate ...

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies ...